Apexium Financial LP Reduces Position in Johnson & Johnson $JNJ

Key Points

• Apexium Financial LP has reduced its stake in Johnson & Johnson by 8.9%, now holding 21,856 shares valued at approximately $3.34 million.
• Recent analyst reports have upgraded Johnson & Johnson's stock, with price targets raised by institutions including Morgan Stanley and HSBC, indicating a positive market outlook.
• Johnson & Johnson recently declared a dividend of $1.30 per share, resulting in an annualized dividend yield of 2.8%.

Apexium Financial LP reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,856 shares of the company's stock after selling 2,133 shares during the quarter. Apexium Financial LP's holdings in Johnson & Johnson were worth $3,338,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $52,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Morgan Stanley increased their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. HSBC lifted their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. The Goldman Sachs Group increased their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research report on Friday, September 19th. Finally, Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an "overweight" rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $188.88.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 1.4%

Shares of JNJ opened at $188.51 on Monday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.78. The stock's 50-day moving average is $176.18 and its two-hundred day moving average is $162.83. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market cap of $453.98 billion, a PE ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.